Cargando…
CD24-Fc suppression of immune related adverse events in a therapeutic cancer vaccine model of murine neuroblastoma
INTRODUCTION: The combination of Myc-suppressed whole tumor cells with checkpoint inhibitors targeting CTLA-4 and PD-L1 generates a potent therapeutic cancer vaccine in a mouse neuroblastoma model. As immunotherapies translate from pre-clinical to clinical trials, the potential immune-related advers...
Autores principales: | Wu, Xiaofang, Srinivasan, Priya, Basu, Mousumi, Zimmerman, Talia, Li, Samuel, Wang, Yin, Zheng, Pan, Liu, Yang, Sandler, Anthony David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10279976/ https://www.ncbi.nlm.nih.gov/pubmed/37346042 http://dx.doi.org/10.3389/fimmu.2023.1176370 |
Ejemplares similares
-
PD-L1 checkpoint inhibition and anti-CTLA-4 whole tumor cell vaccination counter adaptive immune resistance: A mouse neuroblastoma model that mimics human disease
por: Srinivasan, Priya, et al.
Publicado: (2018) -
MYC oncogene is associated with suppression of tumor immunity and targeting Myc induces tumor cell immunogenicity for therapeutic whole cell vaccination
por: Wu, Xiaofang, et al.
Publicado: (2021) -
CD24Fc ameliorates immune-related adverse events while preserving anti-tumor therapeutic effect
por: Liu, Mingyue, et al.
Publicado: (2022) -
Tumor Apolipoprotein E is a key checkpoint blocking anti-tumor immunity in mouse melanoma
por: Wu, Xiaofang, et al.
Publicado: (2022) -
CD24Fc: an emerging COVID-19 therapy
por: Eckhardt, Christina M, et al.
Publicado: (2022)